C
Carla S. Coffin
Researcher at University of Calgary
Publications - 146
Citations - 3410
Carla S. Coffin is an academic researcher from University of Calgary. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 28, co-authored 115 publications receiving 2729 citations. Previous affiliations of Carla S. Coffin include St. John's University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
A Population-Based Study of Pyogenic Liver Abscesses in the United States: Incidence, Mortality, and Temporal Trends
Liisa Meddings,Robert P. Myers,James Hubbard,Abdel Aziz M. Shaheen,Kevin B. Laupland,Elijah Dixon,Carla S. Coffin,Gilaad G. Kaplan +7 more
TL;DR: The incidence of PLA is increasing and is associated with significant mortality that is attributable to several modifiable risk factors, including comorbidities, interventions, and bacterial cultures.
Journal ArticleDOI
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
E.J. Gane,Young-Suk Lim,Stuart C. Gordon,Kumar Visvanathan,Eric Sicard,Richard N. Fedorak,Stuart K. Roberts,Benedetta Massetto,Zhishen Ye,Stefan Pflanz,Kimberly L. Garrison,Anuj Gaggar,G. Mani Subramanian,John G. McHutchison,Shyamasundaran Kottilil,B. Freilich,Carla S. Coffin,Wendy Cheng,Yoon Jun Kim +18 more
TL;DR: Oral GS-9620 was safe, well tolerated, and associated with induction of peripheral ISG15 production in the absence of significant systemic IFN-alpha levels or related symptoms in patients with chronic hepatitis B.
Journal ArticleDOI
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.
Kelly W. Burak,Mark G. Swain,Tania Santodomingo-Garzon,Samuel S. Lee,Stefan J. Urbanski,Alexander I. Aspinall,Carla S. Coffin,Robert P. Myers +7 more
TL;DR: Rituximab was safe, well tolerated and resulted in biochemical improvement in subjects with refractory AIH, and these results support further investigation of rituxIMab as a treatment for AIH.
Journal ArticleDOI
Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis.
Tomasz I. Michalak,Ingrid U. Pardoe,Carla S. Coffin,Norma D. Churchill,Dion S. Freake,Paula G. Smith,Colleen L. Trelegan +6 more
TL;DR: It is revealed that low levels of infectious WHV and residual hepatic inflammation usually continue for life after resolution of hepatitis and that this recovery does not avert HCC development, and that, in addition to the liver, the lymphatic system is the site of the occult lifelong maintenance of replicating hepadnavirus.
Journal ArticleDOI
Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
Matthew Shale,Cynthia H. Seow,Carla S. Coffin,Gilaad G. Kaplan,Remo Panaccione,Subrata Ghosh +5 more
TL;DR: This data indicates that treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease and the risk of opportunistic infection is recognized is not widely adopted in practice.